- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06619912
Dexmedetomidine bij het verminderen van postoperatief delirium bij hartchirurgiepatiënten met preoperatieve slaapstoornissen (DREAMS)
Dexmedetomidine bij het verminderen van postoperatief delirium bij hartchirurgiepatiënten met preoperatieve slaapstoornissen: een single-center, dubbelblinde, gecontroleerde studie
Delirium is a common consequence of cardiac surgery and associates with poor outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Dexmedetomidine may be effective in reducing delirium. The aim of this study was to demonstrate preoperative dexmedetomidine nasal spray in cardiac surgery patients can reduce postoperative delirium by improving preoperative sleep.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Due to special reasons such as surgical trauma, irritability, extracorporeal circulation, the incidence of postoperative delirium (POD) after cardiovascular surgery ranges from 26% to 52%. POD is an acute organic brain syndrome characterised by cognitive impairment and alteration of consciousness. The implications of this acute form of brain injury are profound. Patients who experience delirium are more likely to experience increased short- and long-term mortality, decrease in long-term cognitive function, increase in hospital length of stay and increased complications of hospital care. Given the numerous adverse effects of POD, it is crucial to explore the mechanisms for the prevention and management of POD.
Dexmedetomidine (Dex) is a highly selective α 2-adrenergic receptor agonist that produces sedative and hypnotic effects by activating the α 2-adrenergic receptor in the brainstem locus coeruleus, and has a certain neuroprotective effect. In recent years, the prevention of postoperative delirium by Dex has been a hot topic in the field of anesthesia. However, recent studies have found contradictory conclusions on aforementioned topic.
The heterogeneity of the subject population may be the reason for the current contradictory conclusions. Tang et al. conducted a meta-analysis of all RCTs regarding perioperative sleep interventions and postoperative delirium, and found that in the subgroup where interventions effectively improved patients' sleep quality, the effect of reducing the incidence of postoperative delirium was more significant. At the same time, the incidence of delirium did not decrease in the subgroup where sleep quality was not improved. Sleep disorders play a crucial role in the pathogenesis of POD.
In this DREAMS study, we plan to conduct a single center double-blind randomized controlled trial involving patients undergoing extracorporeal circulation cardiac surgery to explore whether administering Dex nasal spray the night before surgery and 15 minutes before anesthesia induction can improve preoperative sleep quality and reduce the incidence of postoperative delirium.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Xijing Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 18 years or older.
- Cardiac surgery with cardiopulmonary bypass.
- Ability to provide consent.
Exclusion Criteria:
- Preoperative schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, history of neurosurgery, or Mini-mental State Examination(MMSE) score: illiteracy<17, primary school level<20, high school level <24.
- Patients with sick sinus syndrome, severe sinus bradycardia (heart rate<50 beats/minute), grade II or above atrioventricular block, and no pacemaker implanted.
- Unable to communicate due to coma, severe dementia, or language barriers prior to surgery.
- Patients with severe liver dysfunction (Child Pugh C grade), renal dysfunction (preoperative dialysis), ASA grade V or expected survival ≤ 24 hours.
- Heart transplant surgery
- Surgery for congenital heart disease.
- Deep hypothermic circulatory arrest surgery.
- Already enrolled in other study patients.
- Refuse to participate.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dexmedetomidine group
The Dexmedetomidine group will receive dexmedetomidine nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 15 minutes before induction. |
Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 15 minutes before induction. |
|
Geen tussenkomst: Control group
In the control group, the treatment is sodium chloride 0.9% nasal spray. Follows the same rules as in the experimental group. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Postoperative delirium occurrence
Tijdsspanne: within 1 week after operation
|
Delirium occurrence was evaluated with confusion assessment method for the ICU(CAM- ICU) or 3-Minute Confusion Assessment Method (3D-CAM) two times per day during the 7 days following surgery. |
within 1 week after operation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Delirium severity measurement
Tijdsspanne: 1week after surgery
|
Delirium severity is assessed using Confusion Assessment Method for the intensive care unit (CAM-ICU)-7, score 3-5 is considered as mild to moderate delirium, score 6-7 is considered as severe delirium |
1week after surgery
|
|
Delirium subtypes
Tijdsspanne: 1week after surgery
|
Hyperactive POD was defined as a RASS score of +1 to +4 accompanying a positive CAM-ICU/3D-CAM, hypoactive POD was defined as a RASS score of -3 to 0 accompanying a positive CAM-ICU/3D-CAM, mixed POD was defined by simultaneous or sequential exhibition of hypoactive and hyperactive manifestationscare unit (CAM-ICU)-7, score 3-5 is considered as mild to moderate delirium, score 6-7 is considered as severe delirium |
1week after surgery
|
|
Duration of delirium
Tijdsspanne: 1week after surgery
|
Duration of delirium is assessed using Confusion Assessment Method for the intensive care unit (CAM-ICU) or 3-Minute Confusion Assessment Method (3D-CAM) |
1week after surgery
|
|
Hospital length of stay.
Tijdsspanne: From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
|
Hospital length of stay. |
From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
|
|
In- hospital mortality
Tijdsspanne: From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
|
In- hospital mortality |
From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
|
|
NRS score of sleep during the first night after surgery
Tijdsspanne: The first night after surgery
|
NRS score of sleep during the first night after surgery |
The first night after surgery
|
|
Postoperative anxiety and depression
Tijdsspanne: 1week after surgery
|
Postoperative anxiety and depression are assessed using Hospital Anxiety and Depression Scale (HADS) |
1week after surgery
|
|
Pain intensity
Tijdsspanne: 1week after surgery
|
1) Pain intensity is assessed using the NRS at rest and during movement daily for 7 postoperative days |
1week after surgery
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Postoperative occurence of AKI
Tijdsspanne: 1week after surgery
|
AKI occurrence was evaluated with KIDGO guideline during the 7 days following surgery. |
1week after surgery
|
|
Plasma concentration of pTau-217
Tijdsspanne: 24h after surgery
|
Preoperative plasma pTau-217 level is detected after the second dose of the test drug is conducted, and the postoperative plasma pTau-217 level is detected 24 hours after surgery. Plasma pTau-217 level is determined using the Quanterix method that is based on ultrasensitive Simoa technology,on an HD-X analytical platform. |
24h after surgery
|
|
Postoperative occurence of atrial fibrillation
Tijdsspanne: 1week after surgery
|
Postoperative occurence of atrial fibrillation |
1week after surgery
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Chong Lei, M.D., phd, Xijing Hospital
Publicaties en nuttige links
Algemene publicaties
- Wu M, Liang Y, Dai Z, Wang S. Perioperative dexmedetomidine reduces delirium after cardiac surgery: A meta-analysis of randomized controlled trials. J Clin Anesth. 2018 Nov;50:33-42. doi: 10.1016/j.jclinane.2018.06.045. Epub 2018 Jun 27.
- Turan A, Duncan A, Leung S, Karimi N, Fang J, Mao G, Hargrave J, Gillinov M, Trombetta C, Ayad S, Hassan M, Feider A, Howard-Quijano K, Ruetzler K, Sessler DI; DECADE Study Group. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet. 2020 Jul 18;396(10245):177-185. doi: 10.1016/S0140-6736(20)30631-0.
- Zhang Z, Yang X, Qin Y, Gao B, Wang Y, Ji J, Gao J, Huang M, Wang L, Zheng Z, Lei C. Intranasal dexmedetomidine in reducing postoperative delirium among cardiac surgery patients by improving sleep quality in China (DREAMS): study protocol for a single-centre, double-blind, randomised controlled trial. BMJ Open. 2026 Apr 21;16(4):e110057. doi: 10.1136/bmjopen-2025-110057.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Postoperatieve complicaties
- Pathologische processen
- Verwardheid
- Neurologische gedragsmanifestaties
- Neurocognitieve stoornissen
- Delirium
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Ontstaan Delirium
Andere studie-ID-nummers
- KY20242259
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data that underline the results reported in this article, after deidentification.
IPD-tijdsbestek voor delen
beginning 12 months
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .